Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering - Dianthus Therapeutics (NASDAQ:DNTH)

Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering - Dianthus Therapeutics (NASDAQ:DNTH)

NEW YORK and WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH) ("Dianthus" or the "Company"), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it has commenced an underwritten public offering of $400 million of shares of its common stock or, in lieu of common stock to certain investors …

Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering

HC Wainwright Increases Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $130.00

Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) had its price objective boosted by analysts at HC Wainwright from $47.00 to $130.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 69.50% from […]